A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
HYPOTHESES
1. Bolus administration of total abciximab dose provides superior maximal and mean platelet
aggregation inhibition (PAI) compared with standard bolus (0.25 mg/kg) administration.
2. Total dose of abciximab can be given as a single bolus and is more effective than bolus
(0.25 mg/kg) + 12 hrs infusion in terms of acute and mid-term angiographic and clinical
results.
3. Intracoronary (ic) abciximab administration is more effective than intravenous (iv)
route of administration in terms of acute and mid-term angiographic and clinical
results.
4. There is a relationship between PAI and angiographic perfusion scores.
5. Routine use of sirolimus-eluting stents (Cypher, Cordis) in primary-PCI is associated
with a low rate of target vessel revascularization and complications.
6. Cardiac MRI early and late after primary-PCI provides detailed information on myocardial
injury and irreversible necrosis, which are correlated with angiographic perfusion
scores.
7. After uncomplicated trans-radial PCI, patients can be retransferred early to their
referring center.
Phase:
Phase 4
Details
Lead Sponsor:
Laval University
Collaborators:
Cordis Corporation Eli Lilly and Company Quebec Heart Institute
Treatments:
Abciximab Antibodies, Monoclonal Immunoglobulin Fab Fragments